Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients
Prospectively Defined PD-L1 Positive Patients Achieved Median Overall Survival of 42 Months DURHAM, NC / ACCESSWIRE / November 20, 2019...